Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 209

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 209
---
413 |     |         | - |     |         | - |     |       | 15,144,413 |
| Total                                                   |     | $                          | 23,152,014 |     | $       | - |     | $       | - |     | $     | 23,152,014 |

|                                                         |     | Fair Value Measurements at 
 June 30, 2024              |            |     |         |   |     |         |   |     |       |            |
|:--------------------------------------------------------|:----|:---------------------------|-----------:|:----|:--------|:--|:----|:--------|:--|:----|:------|-----------:|
|                                                         |     | Level 1                    |            |     | Level 2 |   |     | Level 3 |   |     | Total |            |
| Cash                                                    |     | $                          | 12,763,941 |     | $       | - |     | $       | - |     | $     | 12,763,941 |
| U.S. Treasury Bills due in 3 months or less at purchase |     |                            | 11,079,857 |     |         | - |     |         | - |     |       | 11,079,857 |
| Total                                                   |     | $                          | 23,843,798 |     | $       | - |     | $       | - |     | $     | 23,843,798 |

| 8. | Equity Transactions |

Issuance of common stock for cash

On March 6, 2024, the Company closed a best efforts
public offering (the “Offering”) of 15,000,000
shares (the “Shares”) of its Common Stock, pre-funded warrants (the “Pre-funded Warrants”) to purchase
6,000,000
shares of Common Stock, and warrants to purchase up to 10,500,000
shares of Common Stock (the “Common Warrants”) at a combined public offering price of $1.00
per Share, or Pre-funded Warrant, and the associated Common Warrant. The Common Warrants have an exercise price of $ 1.50 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance.The gross proceeds to the Company from the Offering were approximately $21.0
million, before deducting placement agent fees and